Traxoprodil

Traxoprodil is a drug that acts as an NMDA antagonist, specifically blocking the NMDA receptor subtype. It was initially developed for the treatment of stroke and was later investigated for the treatment of schizophrenia and other conditions. However, it was discontinued in clinical trials due to adverse side effects.

Pharmacology

Traxoprodil is a selective antagonist of the NMDA receptor, a type of glutamate receptor. It specifically blocks the NR2B subunit of the NMDA receptor. This action is thought to be responsible for its neuroprotective effects in conditions such as stroke.

Clinical trials

Traxoprodil was initially developed by Pfizer for the treatment of acute ischemic stroke. It entered Phase II clinical trials for this indication but was discontinued due to a lack of efficacy.

The drug was later investigated for the treatment of schizophrenia. It was hypothesized that NMDA receptor antagonists might be effective in treating the negative symptoms of schizophrenia, which are not well controlled by existing medications. However, traxoprodil was again discontinued in clinical trials, this time due to adverse side effects.

Side effects

The most common side effects reported in clinical trials of traxoprodil were dizziness, nausea, and headache. Some patients also experienced hallucinations, which led to the discontinuation of the drug in trials for schizophrenia.

See also

• NMDA receptor antagonist
• Glutamate receptor
• Stroke
• Schizophrenia

Traxoprodil Resources
Latest articles Most recent articles Ongoing trials	Wikipedia